Table 5.

Total expenses per patient stratified by BMI, socioeconomic status, and insulin use

		Costs US $		Pre-SHE vs. post-SHE		Between-group comparison
		1 month pre-SHE	1 month post-SHE	Change (%)	P valueb	P value
T1D
BMI, kg/m2 (n)	<25 (172)	441	740	67	0.004	0.865c
	26–30 (80)	571	677	18	0.173
	>31 (30)	531	646	21	0.192
Socioeconomic statusa (n)	Low (37)	638	708	10	0.839	0.680c
	Medium (115)	596	769	29	0.051
	High (72)	333	656	96	0.037
Insulin use (n)	Yes (271)	494	677	36	0.001	0.883d
	No (13)	298	1366	357	0.650
Charlson comorbidity indexe (n)	Low (166)	448	612	36	0.008	0.385c
	Medium (88)	431	730	69	0.212
	High (30)	849	1177	38	0.072
HbA1c (n)	≤7% (99)	538	776	44	0.061	0.984c
	7–9% (122)	420	541	28	0.013
	>9% (61)	530	899	69	0.227
T2D
BMI, kg/m2 (n)	<25 (908)	652	1271	94	<0.001	0.574c
	26–30 (1311)	538	990	83	<0.001
	>31 (1358)	564	1007	78	<0.001
Socioeconomic statusa (n)	Low (563)	590	955	61	<0.001	0.528c
	Medium (1600)	603	1187	96	<0.001
	High (1057)	589	1139	93	<0.001
Insulin use (n)	Yes (1210)	687	1363	98	<0.001	0.187d
	No (2481)	558	1003	79	<0.001
Charlson comorbidity indexe (n)	Low (776)	315	552	75	<0.001	<0.001c
	Medium (1056)	483	865	78	<0.001
	High (1859)	787	1504	91	<0.001
HbA1c (n)	≤7% (1870)	600	1156	92	<0.001	0.882c
	7–9% (1382)	568	1036	82	<0.001
	>9% (436)	712	1243	74	<0.001

BMI body mass index, SHE severe hypoglycemic event, T1D type 1 diabetes, T2D type 2 diabetes

^aSocioeconomic status: Residential socioeconomic index ranging from 1 (lowest) to 20 (highest); low 1–6; medium 7–13; high 14–20

^bStatistical analysis based on a Wilcoxon signed-rank test

^cStatistical analysis based on a Kruskal–Wallis test

^dStatistical analysis based on a Mann–Whitney test

^eCharlson comorbidity index: comorbidity index ranging from 1 (lowest) to 16 (highest); low ≤1; medium 2–3; high ≥4